IGLV3-1 and cancer: Even though sEVs B cell markers expression was invariant between control and cancer, IGLV3-1 was significantly upregulated, after correcting for multiple testing (>one order of magnitude), in sEVs BAL fraction from cancer patients compared to control (Table S1).